☰

Yingjuan Lu, Ph.D. - Publications

Affiliations: 
2000 Purdue University, West Lafayette, IN, United States 
Area:
ligand-targeted imaging and therapeutic agents for the diagnosis and treatment of important human diseases
Tree Info Similar researchers PubMed Report error

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Lu YJ, Wheeler LW, Chu H, Kleindl PJ, Pugh M, You F, Rao S, Garcia G, Wu HY, da Cunha AP, Johnson R, Westrick E, Cross V, Lloyd A, Dircksen C, et al. Targeting folate receptor beta on monocytes/macrophages renders rapid inflammation resolution independent of root causes. Cell Reports. Medicine. 2: 100422. PMID 34755134 DOI: 10.1016/j.xcrm.2021.100422  0.612
2021 Elo P, Li XG, Liljenbäck H, Gardberg M, Moisio O, Miner M, Virta J, Saraste A, Srinivasarao M, Pugh M, Low PS, Knuuti J, Jalkanen S, Airas L, Lu YJ, et al. Efficacy and tolerability of folate-aminopterin therapy in a rat focal model of multiple sclerosis. Journal of Neuroinflammation. 18: 30. PMID 33472663 DOI: 10.1186/s12974-021-02073-7  0.39
2019 Chu H, Shillingford JM, Reddy JA, Westrick E, Nelson M, Wang EZ, Parker N, Felten AE, Vaughn J, Xu LC, Lu Y, Vlahov IR, Leamon CP. Detecting functional and accessible folate receptor expression in cancer and polycystic kidneys. Molecular Pharmaceutics. PMID 31356752 DOI: 10.1021/Acs.Molpharmaceut.9B00624  0.461
2019 Lee YG, Chu H, Lu Y, Leamon CP, Srinivasarao M, Putt KS, Low PS. Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters. Nature Communications. 10: 2681. PMID 31213606 DOI: 10.1038/S41467-019-10565-7  0.637
2019 Lu YJ, Chu H, Wheeler LW, Nelson M, Westrick E, Matthaei JF, Cardle II, Johnson A, Gustafson J, Parker N, Vetzel M, Xu LC, Wang EZ, Jensen MC, Klein PJ, et al. Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies. Frontiers in Oncology. 9: 151. PMID 30941303 DOI: 10.3389/Fonc.2019.00151  0.663
2018 Chu H, Lu Y, Lee YG, Wheeler L, Nelson M, Westrick E, Vetzel M, Klein PJ, Low PS, Leamon CP. Abstract 2546: Regulation of CAR-T cell therapy in real time using bispecific small molecule adaptors and monospecific competitors Cancer Research. 78: 2546-2546. DOI: 10.1158/1538-7445.Am2018-2546  0.666
2017 Lu Y, Wheeler LW, Cross VA, Westrick EM, Lloyd AM, Johnson TP, Parker NL, Leamon CP. Abstract 4574: Combinatorial strategies of folate receptor-targeted chemotherapy guided by improved understanding of tumor microenvironment and immunomodulation Cancer Research. 77: 4574-4574. DOI: 10.1158/1538-7445.Am2017-4574  0.442
2017 Chu H, Shillingford JM, Parker N, Nelson M, Vaughn JF, Felten A, Lu Y, Reddy JA, Vlahov IR, Leamon CP. Abstract 4017: Development and application of an immunohistochemistry-based assay for evaluating functional and accessible folate receptor expressionin vivo Cancer Research. 77: 4017-4017. DOI: 10.1158/1538-7445.Am2017-4017  0.49
2017 Lu Y, Johnson TP, Wheeler LW, Lloyd AM, Cross VA, Westrick EM, Parker NL, Leamon CP. Abstract 3670: Treatment of epithelial ovarian cancer with folate receptor (α/β) targeted chemotherapy is enhanced by CTLA-4 blockade: Learning from animal models Cancer Research. 77: 3670-3670. DOI: 10.1158/1538-7445.Am2017-3670  0.512
2017 Lu Y, Parker NL, Chu H, Pugh MR, Rao SI, Klein PJ, Ritchie MF, Myer LD, Jaskowiak J, Leamon CP. Abstract 2057: Evaluation of anti-tumor efficacy of EC1456 in low-passage and pre-treated patient-derived xenograft models of triple-negative breast cancer Cancer Research. 77: 2057-2057. DOI: 10.1158/1538-7445.Am2017-2057  0.599
2016 Bandara NA, Bates CD, Lu Y, Hoylman EK, Low PS. Folate-Hapten Mediated Immunotherapy Synergizes with Vascular Endothelial Growth Factor Receptor Inhibitors in Treating Murine Models of Cancer. Molecular Cancer Therapeutics. PMID 27980109 DOI: 10.1158/1535-7163.Mct-16-0569  0.633
2015 Lu YJ, Chang SH, Ye JT, Ye YS, Yu YS. Finite Element Analysis of Bone Stress around Micro-Implants of Different Diameters and Lengths with Application of a Single or Composite Torque Force. Plos One. 10: e0144744. PMID 26659581 DOI: 10.1371/journal.pone.0144744  0.384
2015 Kim J, Singh AK, Takata Y, Lin K, Shen J, Lu Y, Kerenyi MA, Orkin SH, Chen T. LSD1 is essential for oocyte meiotic progression by regulating CDC25B expression in mice. Nature Communications. 6: 10116. PMID 26626423 DOI: 10.1038/Ncomms10116  0.316
2015 Lu Y, Liu X, Wang W, Cheng J, Yan H, Tang C, Kim JK, Luo Y. Hierarchical, porous CuS microspheres integrated with carbon nanotubes for high-performance supercapacitors. Scientific Reports. 5: 16584. PMID 26568518 DOI: 10.1038/Srep16584  0.301
2015 Lu Y, Parker N, Kleindl PJ, Cross VA, Wollak K, Westrick E, Stinnette TW, Gehrke MA, Wang K, Santhapuram HK, You F, Hahn SJ, Vaughn JF, Klein PJ, Vlahov IR, et al. Anti-Inflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor Everolimus. Molecular Medicine (Cambridge, Mass.). PMID 26181632 DOI: 10.2119/Molmed.2015.00040  0.545
2015 Wheeler LW, Lu Y, Cross V, Lloyd A, Parker N, Qi L, Wang K, Wang I, Hahn S, Vaughn J, Vlahov IP, Low PS, Leamon CP. Abstract 4495: Small molecule approach for targeting tumor-associated macrophages via a functional FRβ Cancer Research. 75: 4495-4495. DOI: 10.1158/1538-7445.Am2015-4495  0.606
2014 Amato RJ, Shetty A, Lu Y, Ellis PR, Mohlere V, Carnahan N, Low PS. A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 37: 237-44. PMID 24714357 DOI: 10.1097/Cji.0000000000000029  0.486
2014 Lu Y, Wollak KN, Cross VA, Westrick E, Wheeler LW, Stinnette TW, Vaughn JF, Hahn SJ, Xu LC, Vlahov IR, Leamon CP. Folate receptor-targeted aminopterin therapy is highly effective and specific in experimental models of autoimmune uveitis and autoimmune encephalomyelitis Clinical Immunology. 150: 64-77. PMID 24333534 DOI: 10.1016/J.Clim.2013.10.010  0.377
2013 Amato RJ, Shetty A, Lu Y, Ellis R, Low PS. A phase I study of folate immune therapy (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) in patients with renal cell carcinoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 268-75. PMID 23603861 DOI: 10.1097/Cji.0B013E3182917F59  0.494
2012 Henne WA, Kularatne SA, Ayala-López W, Doorneweerd DD, Stinnette TW, Lu Y, Low PS. Synthesis and activity of folate conjugated didemnin B for potential treatment of inflammatory diseases. Bioorganic & Medicinal Chemistry Letters. 22: 709-12. PMID 22100311 DOI: 10.1016/J.Bmcl.2011.10.042  0.706
2012 Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents Advanced Drug Delivery Reviews. 64: 342-352. DOI: 10.1016/j.addr.2012.09.020  0.43
2011 Lu Y, Stinnette TW, Westrick E, Klein PJ, Gehrke MA, Cross VA, Vlahov IR, Low PS, Leamon CP. Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate. Arthritis Research & Therapy. 13: R56. PMID 21463515 DOI: 10.1186/Ar3304  0.526
2009 Lu Y, Klein PJ, Westrick E, Xu LC, Santhapuram HK, Bloomfield A, Howard SJ, Vlahov IR, Ellis PR, Low PS, Leamon CP. Strategy to prevent drug-related hypersensitivity in folate-targeted hapten immunotherapy of cancer. The Aaps Journal. 11: 628-38. PMID 19728104 DOI: 10.1208/S12248-009-9139-7  0.565
2008 Sega EI, Lu Y, Ringor M, Leamon CP, Low PS. Low-dose radiation potentiates the therapeutic efficacy of folate receptor-targeted hapten therapy. International Journal of Radiation Oncology, Biology, Physics. 71: 559-66. PMID 18411004 DOI: 10.1016/J.Ijrobp.2008.02.010  0.749
2007 Lu Y, You F, Vlahov I, Westrick E, Fan M, Low PS, Leamon CP. Folate-targeted dinitrophenyl hapten immunotherapy: effect of linker chemistry on antitumor activity and allergic potential. Molecular Pharmaceutics. 4: 695-706. PMID 17784727 DOI: 10.1021/Mp070050B  0.617
2006 Lu Y, Xu LC, Parker N, Westrick E, Reddy JA, Vetzel M, Low PS, Leamon CP. Preclinical pharmacokinetics, tissue distribution, and antitumor activity of a folate-hapten conjugate-targeted immunotherapy in hapten-immunized mice. Molecular Cancer Therapeutics. 5: 3258-67. PMID 17172429 DOI: 10.1158/1535-7163.Mct-06-0439  0.635
2006 Lu Y, Yang J, Sega E. Issues related to targeted delivery of proteins and peptides. The Aaps Journal. 8: E466-78. PMID 17025264 DOI: 10.1208/Aapsj080355  0.673
2005 Lu Y, Sega E, Low PS. Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells. International Journal of Cancer. Journal International Du Cancer. 116: 710-9. PMID 15828051 DOI: 10.1002/Ijc.21126  0.761
2004 Lu Y, Sega E, Leamon CP, Low PS. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Advanced Drug Delivery Reviews. 56: 1161-76. PMID 15094213 DOI: 10.1016/J.Addr.2004.01.009  0.772
2003 Lu Y, Low PS. Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects. Journal of Controlled Release : Official Journal of the Controlled Release Society. 91: 17-29. PMID 12932634 DOI: 10.1016/S0168-3659(03)00215-3  0.609
2003 Lu Y, Low PS. Targeted immunotherapy of cancer: development of antibody-induced cellular immunity. The Journal of Pharmacy and Pharmacology. 55: 163-7. PMID 12635651 DOI: 10.1211/002235702540  0.54
2002 Lu Y, Low PS. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Advanced Drug Delivery Reviews. 54: 675-93. PMID 12204598 DOI: 10.1016/S0169-409X(02)00042-X  0.619
2002 Lu Y, Low PS. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunology, Immunotherapy : Cii. 51: 153-62. PMID 11941454 DOI: 10.1007/S00262-002-0266-6  0.643
Show low-probability matches.